Back to Journals Journal of Hepatocellular Carcinoma Volume 12 Natural Bioactive Compounds Targeting the Wnt/-Catenin Pathway for the Treatment of Hepatocellular Carcinoma Authors Tian H, Wang P, Shao H Received 19 February 2025 Accepted for publication 11 July 2025 Published 23 July 2025 Volume 2025:12 Pages 16131622 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Ali Hosni Haoyu Tian, Peng Wang, Haibo Shao Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Liaoning, Peoples Republic of China Correspondence: Haibo Shao, Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Peoples Republic of China, Email [email protected] Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis
TOP Therapeutic Indications DOACs are approved in three major clinical settings where oral anticoagulation is commonly used, but are not preferred over warfarin for certain patient populations and are contraindicated for others (see the Initiating a DOAC section below for more information)
DIRECTIONS: As a dietary supplement, take one (1) serving of 20 ml of MEX LIQUID L-CARNITINE 5000 one (1) time daily, preferably before exercise
elegans Feeding through gustatory receptor orthologs and pharyngeal neurons
